PharmaEngine, Inc. (TWO:4162) is honored to be recognized by Taiwan Institute of Directors as one of the 2025 Taiwan Best-In-Class Companies. Moreover, PharmaEngine is proud to be ranked in first place in 2025 Top 10 Profit Champions and second place in 2025 Top 10 Growth Companies.

 

The Best-in-Class award evaluated companies across three key aspects: market performance, fundamentals, and sustainability efforts. The assessment criteria include benchmarks such as the market cap as of March 31, 2025 needs to be between US$100-500 million, consistent profitability over three consecutive years (2022 to 2024), and strong corporate governance scores.

 

 

 

* * *

 

About PharmaEngine, Inc.

PharmaEngine, Inc., headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model”. PharmaEngine has one commercial product, ONIVYDE®, which is currently approved in most major markets including the U.S., Europe, and Asia in combination with fluorouracil and leucovorin for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression. PharmaEngine also conducts, collaborates or licenses-in new drug discovery and development projects. With extensive experience in drug development and project management, we continue to expand our pipeline and accelerate drug development and the subsequent commercialization of new medicines.

 

Media Contact: ChiHsing Chang, Spokesperson/Vice President (info@pharmaengine.com)